<DOC>
	<DOCNO>NCT00002570</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know treatment regimen effective colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness immediate delay fluorouracil plus leucovorin treating patient advance colorectal cancer without sign symptom disease .</brief_summary>
	<brief_title>Immediate Compared With Delayed Chemotherapy Treating Patients With Advanced Colorectal Cancer Without Signs Symptoms Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Compare survival quality life asymptomatic patient advanced colorectal cancer randomize immediate fluorouracil/leucovorin ( 5-FU/CF ) vs. 5-FU/CF delay onset symptom . OUTLINE : Randomized , unblinded study . Arm I : Single-Agent Chemotherapy Drug Modulation . Fluorouracil , 5-FU , NSC-19893 ; Leucovorin calcium , CF , NSC-3590 . Arm II : Observation follow Single-Agent Chemotherapy Drug Modulation . Clinical observation symptomatic ; follow 5-FU ; CF . PROJECTED ACCRUAL : 144 patient enter 4 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm cancer colon rectum locally advance metastatic Primary lesion locate large bowel confirm endoscopy , radiology , surgery Radiologic clinical evidence metastasis subsequent resection require histologic cytologic confirmation unless : Interval primary surgery development metastasis great 5 year OR Primary cancer Dukes ' A B1 Ineligible potentially curative therapy , e.g . : Surgical resection limit hepatic pulmonary metastasis Irradiation locally recurrent colon rectal cancer No minimal symptom related cancer , i.e . : No persistent pain require regular narcotic analgesia No persistent fever great 38 degree C No symptomatic bowel obstruction No persistent nausea require medication No weight loss great 5 kg previous 3 month unless clearly associate cancer ( e.g. , associate surgery intercurrent illness ) Symptomatic relapse/metastases render asymptomatic secondary surgery radiotherapy eligible provide patient remain asymptomatic least 6 week follow treatment No CNS metastases No significant ascites , pleural effusion , pericardial effusion PATIENT CHARACTERISTICS : Age : Adult 80 ( i.e. , legal age sign inform consent accord institutional policy ) Performance status : Karnofsky 90100 % ECOG 0 Hematopoietic : Granulocytes least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal Renal : Creatinine le 2.26 mg/dL Cardiovascular : No arrhythmia Other : No infection No medical condition uncontrolled could aggravate protocol therapy No prior concurrent second cancer except : Nonmelanomatous skin cancer In situ cervical cancer No pregnant woman Adequate contraception require fertile patient Blood/body fluid analyse determine eligibility qualityoflife questionnaire complete within 14 day prior randomization ; image study sit disease complete within 28 day prior randomization PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease local recurrence Prior fluorouracilbased adjuvant therapy allow At least 6 month require completion therapy documentation metastasis recurrence Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : Prior surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>